Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Letrozole + Talimogene laherparepvec |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Letrozole | Femara | Letrozol | Aromatase Inhibitor 3 | Femara (letrozole) is an aromatase inhibitor, which inhibits estrogen synthesis, and is approved for postmenopausal women with hormone receptor positive breast cancer (FDA.gov). |
Talimogene laherparepvec | Imlygic | OncoVEX GM-CSF|T-VEC | Imlygic (talimogene laherparepvec) is a GM-CSF expressing herpes simplex type-1 virus (HSV-1) that selectively infects and lyses tumor cells, and potentially induces a cytotoxic immune response against tumor cells (PMID: 25777572). Imlygic (talimogene laherparepvec) is FDA approved for use in patients with recurrent melanoma (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03554044 | Phase I | Letrozole + Talimogene laherparepvec Talimogene laherparepvec + Tamoxifen Exemestane + Talimogene laherparepvec Fulvestrant + Talimogene laherparepvec Anastrozole + Talimogene laherparepvec Nab-paclitaxel + Talimogene laherparepvec Carboplatin + Gemcitabine + Talimogene laherparepvec Paclitaxel + Talimogene laherparepvec | Talimogene Laherparepvec With Chemotherapy or Endocrine Therapy in Treating Participants With Metastatic, Unresectable, or Recurrent HER2- Negative Breast Cancer | Active, not recruiting | USA | 0 |